Comparison of [18F]FDG and [68  Ga]pentixafor PET/CT in Nasopharyngeal Carcinoma

Conclusions[68 Ga]pentixafor is a promising imaging tracer for detecting primary and metastatic NPC. [68 Ga]pentixafor PET/CT is comparable to [18F]FDG PET/CT in the detection rate of primary tumors and metastatic cervical lymph nodes in nasopharyngeal carcinoma, but [68 Ga]pentixafor uptake was heterogeneous. [68 Ga]pentixafor PET/CT may help select patients most likely to benefit from CXCR4-directed endoradiotherapy.Clinical trial registration No.: ChiCTR2200065902
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research